Vakzine Projekt Management GmbH
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Subsidiary
- Established
- 2002-01-01
- Employees
- -
- Market Cap
- -
Study to Assess VPM1002 in Reducing Hospital Admissions and/or Severe Respiratory Infectious Diseases in Elderly in COVID-19 Pandemic
Phase 3
Completed
- Conditions
- Infection, Respiratory Tract
- Interventions
- Biological: VPM1002Biological: Placebo
- First Posted Date
- 2020-06-17
- Last Posted Date
- 2021-10-26
- Lead Sponsor
- Vakzine Projekt Management GmbH
- Target Recruit Count
- 2038
- Registration Number
- NCT04435379
- Locations
- 🇩🇪
Klinische Forschung Hannover Mitte GmbH, Hannover, Niedersachsen, Germany
🇩🇪Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany
🇩🇪SocraTec R&D GmbH, Erfurt, Thüringen, Germany
Study to Assess VPM1002 in Reducing Healthcare Professionals' Absenteeism in COVID-19 Pandemic
Phase 3
- Conditions
- Infection, Respiratory Tract
- Interventions
- Biological: PlaceboBiological: VPM1002
- First Posted Date
- 2020-05-13
- Last Posted Date
- 2020-09-30
- Lead Sponsor
- Vakzine Projekt Management GmbH
- Target Recruit Count
- 59
- Registration Number
- NCT04387409
- Locations
- 🇩🇪
Ludwig-Maximilians-Universität München, München, Bayern, Germany
🇩🇪Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany
🇩🇪SocraTec R&D GmbH, Erfurt, Thüringen, Germany
Study to Evaluate Safety and Immunogenicity of VPM1002 in Comparison With BCG in Newborn Infants in South Africa
Phase 2
Completed
- Conditions
- Tuberculosis
- Interventions
- Biological: VPM1002Biological: BCG
- First Posted Date
- 2011-11-28
- Last Posted Date
- 2013-10-29
- Lead Sponsor
- Vakzine Projekt Management GmbH
- Target Recruit Count
- 48
- Registration Number
- NCT01479972
- Locations
- 🇿🇦
Children's Infectious Diseases Clinical Research Unit, Tygerberg Hospital, Cape Town, South Africa
Dose-Escalation Study on Safety and Immunogenicity of VPM1002 in Comparison to BCG in Healthy Volunteers in South Africa
Phase 1
Completed
- Conditions
- Tuberculosis
- Interventions
- Biological: commercially available live vaccine BCGBiological: VPM1002 live vaccine
- First Posted Date
- 2010-04-29
- Last Posted Date
- 2011-11-21
- Lead Sponsor
- Vakzine Projekt Management GmbH
- Target Recruit Count
- 24
- Registration Number
- NCT01113281
- Locations
- 🇿🇦
Farmovs-Parexel, Bloemfontein, South Africa
Dose-Escalation Study on Safety and Immunogenicity of VPM1002 in Comparison With BCG in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- TuberculosisHealthy
- Interventions
- Biological: VPM1002Biological: BCG
- First Posted Date
- 2008-09-09
- Last Posted Date
- 2010-05-20
- Lead Sponsor
- Vakzine Projekt Management GmbH
- Target Recruit Count
- 80
- Registration Number
- NCT00749034
- Locations
- 🇩🇪
Focus Clinical Drug Development GmbH, Neuss, Germany
© Copyright 2025. All Rights Reserved by MedPath